BioCentury | Aug 10, 2015
Clinical News

VAC-3S: Additional Phase I data

...tolerated and a produced a dose-dependent immune response. In responders 24 weeks after initial vaccination, InnaVirVax...
...T cells was reduced. Data were presented at the International AIDS Society Symposium in Vancouver. InnaVirVax...
...Dec. 10, 2012). VAC-3S is in the Phase IIa IPROTECT1 trial to treat HIV-1 infection. InnaVirVax S.A....
BioCentury | Jul 13, 2015
Financial News

InnaVirVax completes venture financing

InnaVirVax S.A. , Evry, France Business: Infectious, Cancer Date completed: 2015-07-09 Type: Venture financing Raised: EUR3.6 million ($4 million) Investors: CapDecisif; G1J; Pradeyrol Developpement; Fa Diese; Fonds Regional de Co-Investissement d’Ile-de-France WIR Staff cancer Infectious...
BioCentury | Dec 15, 2014
Clinical News

VAC-3S: Phase II ongoing

...12 weeks or 64 µg/mL VAC-3S every 4 weeks for 3 months without maintenance vaccinations. InnaVirVax S.A....
BioCentury | May 22, 2014
Translation in Brief

Translational tidbits

...stage research projects. Source: BioCentury archives Companies Institutions Business area Disclosed value Purpose Diaxonhit (Euronext:ALEHT); InnaVirVax S.A....
BioCentury | May 5, 2014
Company News

Diaxonhit, InnaVirVax, Institut National de la Sante et de la Recherche Medicale (INSERM) infectious, diagnostic news

...payments, is to respond to unsatisfied medical needs of HIV patients. Diaxonhit (Euronext:ALEHT), Paris, France InnaVirVax S.A....
BioCentury | Dec 9, 2013
Clinical News

VAC-3S: Phase II started

...load of <=50 copies/mm 3 and a CD4+ T cell count of 200-500 cells/mm 3. InnaVirVax S.A....
BioCentury | Dec 10, 2012
Clinical News

VAC-3S: Interim Phase I/IIa data

...of VAC-3S given 4 weeks apart were well tolerated 4 weeks after the third injection. InnaVirVax S.A....
BioCentury | Feb 20, 2012
Financial News

InnaVirVax completes venture financing

InnaVirVax S.A. , Evry, France Business: Infectious, Cancer Date completed: 2/12/12 Type: Venture financing Raised: $4.9 million Investors: Pradeyrol Developpement; Fa Diese; Fonds Regional de Co-Investissement d'Ile-de-France; CapDecisif; G1J WIR Staff cancer Infectious...
BioCentury | Oct 24, 2011
Clinical News

VAC-3S: Phase I/IIa started

...French Phase I/IIa trial to evaluate VAC-3S vaccine in 24 HIV-infected patients receiving antiretroviral therapy. InnaVirVax S.A....
BioCentury | Jul 18, 2011
Clinical News

InnaVirVax preclinical data

...lesion formation. VAC-3S is a gp41 peptide that inhibits decreases in CD4+ T cell count. InnaVirVax S.A....
Items per page:
1 - 10 of 10
BioCentury | Aug 10, 2015
Clinical News

VAC-3S: Additional Phase I data

...tolerated and a produced a dose-dependent immune response. In responders 24 weeks after initial vaccination, InnaVirVax...
...T cells was reduced. Data were presented at the International AIDS Society Symposium in Vancouver. InnaVirVax...
...Dec. 10, 2012). VAC-3S is in the Phase IIa IPROTECT1 trial to treat HIV-1 infection. InnaVirVax S.A....
BioCentury | Jul 13, 2015
Financial News

InnaVirVax completes venture financing

InnaVirVax S.A. , Evry, France Business: Infectious, Cancer Date completed: 2015-07-09 Type: Venture financing Raised: EUR3.6 million ($4 million) Investors: CapDecisif; G1J; Pradeyrol Developpement; Fa Diese; Fonds Regional de Co-Investissement d’Ile-de-France WIR Staff cancer Infectious...
BioCentury | Dec 15, 2014
Clinical News

VAC-3S: Phase II ongoing

...12 weeks or 64 µg/mL VAC-3S every 4 weeks for 3 months without maintenance vaccinations. InnaVirVax S.A....
BioCentury | May 22, 2014
Translation in Brief

Translational tidbits

...stage research projects. Source: BioCentury archives Companies Institutions Business area Disclosed value Purpose Diaxonhit (Euronext:ALEHT); InnaVirVax S.A....
BioCentury | May 5, 2014
Company News

Diaxonhit, InnaVirVax, Institut National de la Sante et de la Recherche Medicale (INSERM) infectious, diagnostic news

...payments, is to respond to unsatisfied medical needs of HIV patients. Diaxonhit (Euronext:ALEHT), Paris, France InnaVirVax S.A....
BioCentury | Dec 9, 2013
Clinical News

VAC-3S: Phase II started

...load of <=50 copies/mm 3 and a CD4+ T cell count of 200-500 cells/mm 3. InnaVirVax S.A....
BioCentury | Dec 10, 2012
Clinical News

VAC-3S: Interim Phase I/IIa data

...of VAC-3S given 4 weeks apart were well tolerated 4 weeks after the third injection. InnaVirVax S.A....
BioCentury | Feb 20, 2012
Financial News

InnaVirVax completes venture financing

InnaVirVax S.A. , Evry, France Business: Infectious, Cancer Date completed: 2/12/12 Type: Venture financing Raised: $4.9 million Investors: Pradeyrol Developpement; Fa Diese; Fonds Regional de Co-Investissement d'Ile-de-France; CapDecisif; G1J WIR Staff cancer Infectious...
BioCentury | Oct 24, 2011
Clinical News

VAC-3S: Phase I/IIa started

...French Phase I/IIa trial to evaluate VAC-3S vaccine in 24 HIV-infected patients receiving antiretroviral therapy. InnaVirVax S.A....
BioCentury | Jul 18, 2011
Clinical News

InnaVirVax preclinical data

...lesion formation. VAC-3S is a gp41 peptide that inhibits decreases in CD4+ T cell count. InnaVirVax S.A....
Items per page:
1 - 10 of 10